<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Medical Genetics - Most viewed articles</title>
		<link>http://www.biomedcentral.com/bmcmedgenet/mostviewed/</link>
		<description>Most viewed articles in last 30 days from BMC Medical Genetics (ISSN 1471-2350) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
         <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/9/59"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/9/58"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/9/55"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/9/56"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/9/53"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/9/57"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/9/60"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/9/45"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/6/7"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/9/66"/>			    
            
            </rdf:Seq>
        </items>
    </channel>
    
		<item rdf:about="http://www.biomedcentral.com/1471-2350/9/59">
            
            <title>Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk</title>
			<description>Background:
Recent genome-wide association (GWA) studies have identified several unsuspected genes associated with type 2 diabetes (T2D) with previously unknown functions. In this investigation, we have examined the role of 9 most significant SNPs reported in GWA studies: [peroxisome proliferator-activated receptor gamma 2 (PPARG2; rs 1801282); insulin-like growth factor two binding protein 2 (IGF2BP2; rs 4402960); cyclin-dependent kinase 5, a regulatory subunit-associated protein1-like 1 (CDK5; rs7754840); a zinc transporter and member of solute carrier family 30 (SLC30A8; rs13266634); a variant found near cyclin-dependent kinase inhibitor 2A (CDKN2A; rs10811661); hematopoietically expressed homeobox (HHEX; rs 1111875); transcription factor-7-like 2 (TCF7L2; rs 10885409); potassium inwardly rectifying channel subfamily J member 11(KCNJ11; rs 5219); and fat mass obesity-associated gene (FTO; rs 9939609)].
Methods:
We genotyped these SNPs in a case-control sample of 918 individuals consisting of 532 T2D cases and 386 normal glucose tolerant (NGT) subjects of an Asian Sikh community from North India. We tested the association between T2D and each SNP using unconditional logistic regression before and after adjusting for age, gender, and other covariates. We also examined the impact of these variants on body mass index (BMI), waist to hip ratio (WHR), fasting insulin, and glucose and lipid levels using multiple linear regression analysis.
Results:
Four of the nine SNPs revealed a significant association with T2D; PPARG2 (Pro12Ala) [odds ratio (OR) 0.12; 95% confidence interval (CI) (0.03&#8211;0.52); p = 0.005], IGF2BP2 [OR 1.37; 95% CI (1.04&#8211;1.82); p = 0.027], TCF7L2 [OR 1.64; 95% CI (1.20&#8211;2.24); p = 0.001] and FTO [OR 1.46; 95% CI (1.11&#8211;1.93); p = 0.007] after adjusting for age, sex and BMI. Multiple linear regression analysis revealed significant association of two of nine investigated loci with diabetes-related quantitative traits. The 'C' (risk) allele of CDK5 (rs 7754840) was significantly associated with decreased HDL-cholesterol levels in both NGT (p = 0.005) and combined (NGT and T2D) (0.005) groups. The less common 'C' (risk) allele of TCF7L2 (rs 10885409) was associated with increased LDL-cholesterol (p = 0.010) in NGT and total and LDL-cholesterol levels (p = 0.008; p = 0.003, respectively) in combined cohort.
Conclusion:
To our knowledge, this is first study reporting the role of some recently emerged loci with T2D in a high risk population of Asian Indian origin. Further investigations are warranted to understand the pathway-based functional implications of these important loci in T2D pathophysiology in different ethnicities.</description>
			<link>http://www.biomedcentral.com/1471-2350/9/59</link>		
			<dc:creator>Dharambir K Sanghera, Lyda Ortega, Shizhong Han, Jairup Singh, Sarju K Ralhan, Gurpreet S Wander, Narinder K Mehra, John J Mulvihill, Robert E Ferrell, Swapan K Nath and Mohammed I Kamboh</dc:creator>
			<dc:source>BMC Medical Genetics 2008, 9:59</dc:source>
			<dc:subject>Number of accesses: 660</dc:subject>
			<dc:date>2008-07-03</dc:date>
			<dc:identifier>doi:10.1186/1471-2350-9-59</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Genetics</prism:publicationName>
					
			
							
					<prism:issn>1471-2350</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>59</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-03</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2350/9/58">
            
            <title>Novel de novo BRCA2 mutation in a patient with a family history of breast cancer</title>
			<description>Background:
BRCA2 germ-line mutations predispose to breast and ovarian cancer. Mutations are widespread and unclassified splice variants are frequently encountered. We describe the parental origin and functional characterization of a novel de novo BRCA2 splice site mutation found in a patient exhibiting a ductal carcinoma at the age of 40.
Methods:
Variations were identified by denaturing high performance liquid chromatography (dHPLC) and sequencing of the BRCA1 and BRCA2 genes. The effect of the mutation on splicing was examined by exon trapping in COS-7 cells and by RT-PCR on RNA isolated from whole blood. The paternity was determined by single nucleotide polymorphism (SNP) microarray analysis. Parental origin of the de novo mutation was determined by establishing mutation-SNP haplotypes by variant specific PCR, while de novo and mosaic status was investigated by sequencing of DNA from leucocytes and carcinoma tissue.
Results:
A novel BRCA2 variant in the splice donor site of exon 21 (nucleotide 8982+1 G&#8594;A/c.8754+1 G&#8594;A) was identified. Exon trapping showed that the mutation activates a cryptic splice site 46 base pairs 3' of exon 21, resulting in the inclusion of a premature stop codon and synthesis of a truncated BRCA2 protein. The aberrant splicing was verified by RT-PCR analysis on RNA isolated from whole blood of the affected patient. The mutation was not found in any of the patient's parents or in the mother's carcinoma, showing it is a de novo mutation. Variant specific PCR indicates that the mutation arose in the male germ-line.
Conclusion:
We conclude that the novel BRCA2 splice variant is a de novo mutation introduced in the male spermatozoa that can be classified as a disease causing mutation.</description>
			<link>http://www.biomedcentral.com/1471-2350/9/58</link>		
			<dc:creator>Thomas V O Hansen, Marie Luise Bisgaard, Lars J&#248;nson, Anders Albrechtsen, Bettina Filtenborg-Barnkob, Hans Eiberg, Bent Ejlertsen and Finn C Nielsen</dc:creator>
			<dc:source>BMC Medical Genetics 2008, 9:58</dc:source>
			<dc:subject>Number of accesses: 625</dc:subject>
			<dc:date>2008-07-02</dc:date>
			<dc:identifier>doi:10.1186/1471-2350-9-58</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Genetics</prism:publicationName>
					
			
							
					<prism:issn>1471-2350</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>58</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-02</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2350/9/55">
            
            <title>Association between LRP5 polymorphism and bone mineral density: a Bayesian meta-analysis</title>
			<description>Background:
The low-density lipoprotein receptor-related protein 5 gene (LRP5) was identified to be linked to the variation in BMD in high bone mass pedigrees. Subsequent population-based studies of the association between the LRP5 gene and BMD have yielded conflicting results. The present study was aimed at examining the association between LRP5 gene and BMD by using meta-analysis.
Methods:
A systematic electronic search of literature was conducted to identify all published studies in English on the association between LRP5 gene and osteoporosis-related phenotypes, including bone mineral density and fracture. BMD data were summarized from individual studies by LRP5 genotype, and a synthesis of data was performed with random-effects meta-analyses. After excluding studies on animal and review papers, there were 19 studies for the synthesis. Among these studies, 10 studies used the rs3736228 (A1330V) polymorphism and reported BMD values.
Results:
The 10 eligible studies comprised 16,705 individuals, with the majority being women (n = 8444), aged between 18 &#8211; 81 years. The overall distribution of genotype frequencies was: AA, 68%, AV and VV, 32%. However, the genotype frequency varied significantly within as well as between ethnic populations. On random-effects meta-analysis, lumbar spine BMD among individuals with the AA genotype was on average 0.018 (95% confidence interval [CI]: 0.012 to 0.023) g/cm2 higher than those with either AV or VV genotype. Similarly, femoral neck BMD among carriers of the AA genotype was 0.011 (95%CI: 0.004 to 0.017) g/cm2 higher than those without the genotype. While there was no significant heterogeneity in the association between the A1330V polymorphism and lumbar spine BMD (p = 0.55), the association was heterogeneous for femoral neck BMD (p = 0.05). The probability that the difference is greater than one standard deviation was 0.34 for femoral neck BMD and 0.54 for lumbar spine BMD.
Conclusion:
These results suggest that there is a modest effect of the A1330V polymorphism on BMD in the general population, and that the modest association may limit its clinical use.</description>
			<link>http://www.biomedcentral.com/1471-2350/9/55</link>		
			<dc:creator>Bich NH Tran, Nguyen D Nguyen, John A Eisman and Tuan V Nguyen</dc:creator>
			<dc:source>BMC Medical Genetics 2008, 9:55</dc:source>
			<dc:subject>Number of accesses: 400</dc:subject>
			<dc:date>2008-06-27</dc:date>
			<dc:identifier>doi:10.1186/1471-2350-9-55</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Genetics</prism:publicationName>
					
			
							
					<prism:issn>1471-2350</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>55</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2350/9/56">
            
            <title>Linkage disequilibrium mapping of a breast cancer susceptibility locus near RAI/PPP1R13L/iASPP</title>
			<description>Background:
Previous results have suggested an association of the region of 19q13.3 with several forms of cancer. In the present study, we investigated 27 public markers within a previously identified 69 kb stretch of chromosome 19q for association with breast cancer by using linkage disequilibrium mapping. The study groups included 434 postmenopausal breast cancer cases and an identical number of individually matched controls.Methods and ResultsStudying one marker at a time, we found a region spanning the gene RAI (alias PPP1R13L or iASPP) and the 5' portion of XPD to be associated with this cancer. The region corresponds to a haplotype block, in which there seems to be very limited recombination in the Danish population. Studying combinations of markers, we found that two to four neighboring markers gave the most consistent and strongest result. The haplotypes with strongest association with cancers were located in the gene RAI and just 3' to the gene. Coinciding peaks were seen in the region of RAI in groups of women of different age.In a follow-up to these results we sequenced 10 cases and 10 controls in a 44 kb region spanning the peaks of association. This revealed 106 polymorphisms, many of which were not in the public databases. We tested an additional 44 of these for association with disease and found a new tandem repeat marker, called RAI-3'd1, located downstream of the transcribed region of RAI, which was more strongly associated with breast cancer than any other marker we have tested (RR = 2.44 (1.41&#8211;4.23, p = 0.0008, all cases; RR = 6.29 (1.49&#8211;26.6), p = 0.01, cases up to 55 years of age).
Conclusion:
We expect the marker RAI-3'd1 to be (part of) the cause for the association of the chromosome 19q13.3 region's association with cancer.</description>
			<link>http://www.biomedcentral.com/1471-2350/9/56</link>		
			<dc:creator>Bj&#248;rn A Nex&#248;, Ulla Vogel, Anja Olsen, Mette Nyegaard, Zuzanna Bukowy, Eszter Rockenbauer, Xiuqing Zhang, Cemile Koca, Mette Mains, Bettina Hansen, Anne Hedemand, Anette Kjeldgaard, Magdalena J Laska, Ole Raaschou-Nielsen, S&#248;ren Cold, Kim Overvad, Anne Tj&#248;nneland, Lars Bolund and Anders D B&#248;rglum</dc:creator>
			<dc:source>BMC Medical Genetics 2008, 9:56</dc:source>
			<dc:subject>Number of accesses: 353</dc:subject>
			<dc:date>2008-06-27</dc:date>
			<dc:identifier>doi:10.1186/1471-2350-9-56</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Genetics</prism:publicationName>
					
			
							
					<prism:issn>1471-2350</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>56</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2350/9/53">
            
            <title>Mutation spectrum of 122 hemophilia A families from Taiwanese population by LD-PCR, DHPLC, multiplex PCR and evaluating the clinical application of HRM</title>
			<description>Background:
Hemophilia A represents the most common and severe inherited hemorrhagic disorder. It is caused by mutations in the F8 gene, which leads to a deficiency or dysfunctional factor VIII protein, an essential cofactor in the factor X activation complex.
Methods:
We used long-distance polymerase chain reaction and denaturing high performance liquid chromatography for mutation scanning of the F8 gene. We designed the competitive multiplex PCR to identify the carrier with exonal deletions. In order to facilitate throughput and minimize the cost of mutation scanning, we also evaluated a new mutation scanning technique, high resolution melting analysis (HRM), as an alternative screening method.
Results:
We presented the results of detailed screening of 122 Taiwanese families with hemophilia A and reported twenty-nine novel mutations. There was one family identified with whole exons deletion, and the carriers were successfully recognized by multiplex PCR. By HRM, the different melting curve patterns were easily identified in 25 out of 28 cases (89%) and 15 out of 15 (100%) carriers. The sensitivity was 93 % (40/43). The overall mutation detection rate of hemophilia A was 100% in this study.
Conclusion:
We proposed a diagnostic strategy for hemophilia A genetic diagnosis. We consider HRM as a powerful screening tool that would provide us with a more cost-effective protocol for hemophilia A mutation identification.</description>
			<link>http://www.biomedcentral.com/1471-2350/9/53</link>		
			<dc:creator>Shin-Yu Lin, Yi-Ning Su, Chia-Cheng Hung, Woei Tsay, Shyh-Shin Chiou, Chieh-Ting Chang, Hong-Nerng Ho and Chien-Nan Lee</dc:creator>
			<dc:source>BMC Medical Genetics 2008, 9:53</dc:source>
			<dc:subject>Number of accesses: 351</dc:subject>
			<dc:date>2008-06-20</dc:date>
			<dc:identifier>doi:10.1186/1471-2350-9-53</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Genetics</prism:publicationName>
					
			
							
					<prism:issn>1471-2350</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>53</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-20</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2350/9/57">
            
            <title>Mitochondrial haplogroup H1 is protective for ischemic stroke in Portuguese patients</title>
			<description>Background:
The genetic contribution to stroke is well established but it has proven difficult to identify the genes and the disease-associated alleles mediating this effect, possibly because only nuclear genes have been intensely investigated so far. Mitochondrial DNA (mtDNA) has been implicated in several disorders having stroke as one of its clinical manifestations. The aim of this case-control study was to assess the contribution of mtDNA polymorphisms and haplogroups to ischemic stroke risk.
Methods:
We genotyped 19 mtDNA single nucleotide polymorphisms (SNPs) defining the major European haplogroups in 534 ischemic stroke patients and 499 controls collected in Portugal, and tested their allelic and haplogroup association with ischemic stroke risk.
Results:
Haplogroup H1 was found to be significantly less frequent in stroke patients than in controls (OR=0.61, 95% CI=0.45-0.83, p=0.001), when comparing each clade against all other haplogroups pooled together. Conversely, the pre-HV/HV and U mtDNA lineages emerge as potential genetic factors conferring risk for stroke (OR=3.14, 95% CI=1.41-7.01, p=0.003, and OR=2.87, 95% CI=1.13-7.28, p=0.021, respectively). SNPs m.3010G>A, m.7028C>T and m.11719G>A strongly influence ischemic stroke risk, their allelic state in haplogroup H1 corroborating its protective effect.
Conclusion:
Our data suggests that mitochondrial haplogroup H1 has an impact on ischemic stroke risk in a Portuguese sample.</description>
			<link>http://www.biomedcentral.com/1471-2350/9/57</link>		
			<dc:creator>Alexandra Rosa, Benedita V Fonseca, Tiago Krug, Helena Manso, Liliana Gouveia, Isabel Albergaria, Gisela Gaspar, Manuel Correia, Miguel Viana-Baptista, Rita Moiron Simoes, Amelia Nogueira Pinto, Ricardo Taipa, Carla Ferreira, Joao Ramalho Fontes, Mario Rui Silva, Joao Paulo Gabriel, Ilda Matos, Gabriela Lopes, Jose M Ferro, Astrid M Vicente and Sofia A Oliveira</dc:creator>
			<dc:source>BMC Medical Genetics 2008, 9:57</dc:source>
			<dc:subject>Number of accesses: 351</dc:subject>
			<dc:date>2008-07-01</dc:date>
			<dc:identifier>doi:10.1186/1471-2350-9-57</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Genetics</prism:publicationName>
					
			
							
					<prism:issn>1471-2350</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>57</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-01</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2350/9/60">
            
            <title>Analytical approaches to detect maternal/fetal genotype incompatibilities that increase risk of pre-eclampsia</title>
			<description>Background:
In utero interactions between incompatible maternal and fetal genotypes are a potential mechanism for the onset or progression of pregnancy related diseases such as pre-eclampsia (PE). However, the optimal analytical approach and study design for evaluating incompatible maternal/offspring genotype combinations is unclear.
Methods:
Using simulation, we estimated the type I error and power of incompatible maternal/offspring genotype models for two analytical approaches: logistic regression used with case-control mother/offspring pairs and the log-linear regression used with case-parent triads. We evaluated a real dataset consisting of maternal/offspring pairs with and without PE for incompatibility effects using the optimal analysis based on the results of the simulation study.
Results:
We identified a single coding scheme for the incompatibility effect that was equally or more powerful than all of the alternative analysis models evaluated, regardless of the true underlying model for the incompatibility effect. In addition, the log-linear regression was more powerful than the logistic regression when the heritability was low, and more robust to adjustment for maternal or fetal effects. For the PE data, this analysis revealed three genes, lymphotoxin alpha (LTA), von Willebrand factor (VWF), and alpha 2 chain of type IV collagen (COL4A2) with possible incompatibility effects.
Conclusion:
The incompatibility model should be evaluated for complications of pregnancy, such as PE, where the genotypes of two individuals may contribute to the presence of disease.</description>
			<link>http://www.biomedcentral.com/1471-2350/9/60</link>		
			<dc:creator>Neeta Parimi, Gerard Tromp, Helena Kuivaniemi, Jyh Kae Nien, Ricardo Gomez, Roberto Romero and Katrina AB Goddard</dc:creator>
			<dc:source>BMC Medical Genetics 2008, 9:60</dc:source>
			<dc:subject>Number of accesses: 348</dc:subject>
			<dc:date>2008-07-03</dc:date>
			<dc:identifier>doi:10.1186/1471-2350-9-60</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Genetics</prism:publicationName>
					
			
							
					<prism:issn>1471-2350</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>60</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-03</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2350/9/45">
            
            <title>The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies</title>
			<description>Background:
Considering that a portion of the heterogeneity amongst previous replication studies may be due to a variable proportion of obese subjects in case-control designs, we assessed the association of genetic variants with type 2 diabetes (T2D) in large groups of obese and non-obese subjects.
Methods:
We genotyped RETN, KCNJ11, HNF4A, HNF1A, GCK, SLC30A8, ENPP1, ADIPOQ, PPARG, and TCF7L2 polymorphisms in 1,283 normoglycemic (NG) and 1,581 T2D obese individuals as well as in 3,189 NG and 1,244 T2D non-obese subjects of European descent, allowing us to examine T2D risk over a wide range of BMI.
Results:
Amongst non-obese individuals, we observed significant T2D associations with HNF1A I27L [odds ratio (OR) = 1.14, P = 0.04], GCK -30G>A (OR = 1.23, P = 0.01), SLC30A8 R325W (OR = 0.87, P = 0.04), and TCF7L2 rs7903146 (OR = 1.89, P = 4.5 &#215; 10-23), and non-significant associations with PPARG Pro12Ala (OR = 0.85, P = 0.14), ADIPOQ -11,377C>G (OR = 1.00, P = 0.97) and ENPP1 K121Q (OR = 0.99, P = 0.94). In obese subjects, associations with T2D were detected with PPARG Pro12Ala (OR = 0.73, P = 0.004), ADIPOQ -11,377C>G (OR = 1.26, P = 0.02), ENPP1 K121Q (OR = 1.30, P = 0.003) and TCF7L2 rs7903146 (OR = 1.30, P = 1.1 &#215; 10-4), and non-significant associations with HNF1A I27L (OR = 0.96, P = 0.53), GCK -30G>A (OR = 1.15, P = 0.12) and SLC30A8 R325W (OR = 0.95, P = 0.44). However, a genotypic heterogeneity was only found for TCF7L2 rs7903146 (P = 3.2 &#215; 10-5) and ENPP1 K121Q (P = 0.02). No association with T2D was found for KCNJ11, RETN, and HNF4A polymorphisms in non-obese or in obese individuals.
Conclusion:
Genetic variants modulating insulin action may have an increased effect on T2D susceptibility in the presence of obesity, whereas genetic variants acting on insulin secretion may have a greater impact on T2D susceptibility in non-obese individuals.</description>
			<link>http://www.biomedcentral.com/1471-2350/9/45</link>		
			<dc:creator>St&#233;phane Cauchi, Kevin T Nead, H&#233;l&#232;ne Choquet, Fritz Horber, Natascha Potoczna, Beverley Balkau, Michel Marre, Guillaume Charpentier, Philippe Froguel and David Meyre</dc:creator>
			<dc:source>BMC Medical Genetics 2008, 9:45</dc:source>
			<dc:subject>Number of accesses: 338</dc:subject>
			<dc:date>2008-05-22</dc:date>
			<dc:identifier>doi:10.1186/1471-2350-9-45</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Genetics</prism:publicationName>
					
			
							
					<prism:issn>1471-2350</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>45</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2350/6/7">
            
            <title>Theories of schizophrenia: a genetic-inflammatory-vascular synthesis</title>
			<description>Background:
Schizophrenia, a relatively common psychiatric syndrome, affects virtually all brain functions yet has eluded explanation for more than 100 years. Whether by developmental and/or degenerative processes, abnormalities of neurons and their synaptic connections have been the recent focus of attention. However, our inability to fathom the pathophysiology of schizophrenia forces us to challenge our theoretical models and beliefs. A search for a more satisfying model to explain aspects of schizophrenia uncovers clues pointing to genetically mediated CNS microvascular inflammatory disease.DiscussionA vascular component to a theory of schizophrenia posits that the physiologic abnormalities leading to illness involve disruption of the exquisitely precise regulation of the delivery of energy and oxygen required for normal brain function. The theory further proposes that abnormalities of CNS metabolism arise because genetically modulated inflammatory reactions damage the microvascular system of the brain in reaction to environmental agents, including infections, hypoxia, and physical trauma. Damage may accumulate with repeated exposure to triggering agents resulting in exacerbation and deterioration, or healing with their removal.There are clear examples of genetic polymorphisms in inflammatory regulators leading to exaggerated inflammatory responses. There is also ample evidence that inflammatory vascular disease of the brain can lead to psychosis, often waxing and waning, and exhibiting a fluctuating course, as seen in schizophrenia. Disturbances of CNS blood flow have repeatedly been observed in people with schizophrenia using old and new technologies. To account for the myriad of behavioral and other curious findings in schizophrenia such as minor physical anomalies, or reported decreased rates of rheumatoid arthritis and highly visible nail fold capillaries, we would have to evoke a process that is systemic such as the vascular and immune/inflammatory systems.SummaryA vascular-inflammatory theory of schizophrenia brings together environmental and genetic factors in a way that can explain the diversity of symptoms and outcomes observed. If these ideas are confirmed, they would lead in new directions for treatments or preventions by avoiding inducers of inflammation or by way of inflammatory modulating agents, thus preventing exaggerated inflammation and consequent triggering of a psychotic episode in genetically predisposed persons.</description>
			<link>http://www.biomedcentral.com/1471-2350/6/7</link>		
			<dc:creator>Daniel R Hanson and Irving I Gottesman</dc:creator>
			<dc:source>BMC Medical Genetics 2005, 6:7</dc:source>
			<dc:subject>Number of accesses: 312</dc:subject>
			<dc:date>2005-02-11</dc:date>
			<dc:identifier>doi:10.1186/1471-2350-6-7</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Genetics</prism:publicationName>
					
			
							
					<prism:issn>1471-2350</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>7</prism:startingPage>
					
			
							
					<prism:publicationDate>2005-02-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2350/9/66">
            
            <title>Investigation of 89 candidate gene variants for effects on all-cause mortality following acute coronary syndrome</title>
			<description>Background:
Many candidate genes have been reported to be risk factors for acute coronary syndrome (ACS), but their impact on clinical prognosis following ACS is unknown.
Methods:
We examined the association of putative genetic risk factors with 3-year post-ACS mortality in 811 ACS survivors at university-affiliated hospitals in Kansas City, Missouri. Through a systematic literature search, we first identified genetic variants reported as susceptibility factors for atherosclerosis or ACS. Restricting our analysis to whites, so as to avoid confounding from racial admixture, we genotyped ACS cases for 89 genetic variants in 72 genes, and performed individual Kaplan-Meier survival analyses. We then performed Cox regression to create multivariate risk prediction models that further minimized potential confounding.
Results:
Of 89 variants tested, 16 were potentially associated with mortality (P &lt; 0.1 for all), of which 6 were significantly associated (P &lt; 0.05) with mortality following ACS. While these findings are not more than what would be expected by chance (P = 0.28), even after Bonferroni correction and adjustment for traditional cardiac risk factors, the IRS1 972Arg variant association (P = 0.001) retained borderline statistical significance (P &lt; 0.1).
Conclusion:
With the possible exception of IRS1, we conclude that multiple candidate genes were not associated with post-ACS mortality in our patient cohort. Because of power limitations, the 16 gene variants with P values &lt; 0.1 may warrant further study. Our data do not support the hypothesis that the remaining 73 genes have substantial, clinically significant association with mortality after an ACS.</description>
			<link>http://www.biomedcentral.com/1471-2350/9/66</link>		
			<dc:creator>Thomas M Morgan, Lan Xiao, Patrick Lyons, Bethany Kassebaum, Harlan M Krumholz and John A Spertus</dc:creator>
			<dc:source>BMC Medical Genetics 2008, 9:66</dc:source>
			<dc:subject>Number of accesses: 302</dc:subject>
			<dc:date>2008-07-12</dc:date>
			<dc:identifier>doi:10.1186/1471-2350-9-66</dc:identifier>
			
			
							
					<prism:publicationName>BMC Medical Genetics</prism:publicationName>
					
			
							
					<prism:issn>1471-2350</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>66</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
	<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
